Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
The approval marks a major milestone in the global fight against antimicrobial resistance
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
The conference highlighted research suggesting that deuterium levels may influence key biological processes
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Subscribe To Our Newsletter & Stay Updated
